Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy

Nat Commun. 2022 Sep 21;13(1):5523. doi: 10.1038/s41467-022-33248-2.

Abstract

Retinoblastoma (RB) is a cancer that forms in the developing retina of babies and toddlers. The goal of therapy is to cure the tumor, save the eye and maximize vision. However, it is difficult to predict which eyes are likely to respond to therapy. Predictive molecular biomarkers are needed to guide prognosis and optimize treatment decisions. Direct tumor biopsy is not an option for this cancer; however, the aqueous humor (AH) is an alternate source of tumor-derived cell-free DNA (cfDNA). Here we show that DNA methylation profiling of the AH is a valid method to identify the methylation status of RB tumors. We identify 294 genes directly regulated by methylation that are implicated in p53 tumor suppressor (RB1, p53, p21, and p16) and oncogenic (E2F) pathways. Finally, we use AH to characterize molecular subtypes that can potentially be used to predict the likelihood of treatment success for retinoblastoma patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aqueous Humor / metabolism
  • Cell-Free Nucleic Acids* / metabolism
  • DNA Methylation / genetics
  • Humans
  • Infant
  • Liquid Biopsy
  • Retinal Neoplasms* / metabolism
  • Retinoblastoma* / pathology
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Cell-Free Nucleic Acids
  • Tumor Suppressor Protein p53